Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

2 Mar 2021 07:00

RNS Number : 7803Q
MyCelx Technologies Corporation
02 March 2021
 

2 March 2021

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.

 

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and air technology experts, supplying customers with cost-effective, future-proof solutions that optimise production and protect the environment, is pleased to announce a trading update on the Company's operations.

 

MYCELX has made a strong start to the year with two project extensions signed with customers in the Kingdom of Saudi Arabia. These projects confirm that MYCELX's superior solutions continue to support its customers' efforts to optimise production, increase cost savings and improve energy efficiency. During Q1, the Company will commence delivery of the equipment for its third sale to Nigeria.

 

Following product development initiatives in 2020, carried out to enhance its REGEN solution, the Company has secured a paid trial. This will demonstrate REGEN's superior performance over other water treatment offerings for Enhanced Oil Recovery ("EOR") production. The Company has commenced fabrication of this system in Q1 and anticipates that a successful outcome of this trial will lead to heightened interest in the REGEN product offering by leading EOR producers.

 

The value of these project extensions, trial and capital sale amounts to $3.5m in revenue for 2021.

 

As previously reported, the impact of the COVID-19 pandemic and the resulting disruption to its core markets meant that 2020 was an extremely challenging year for the business, with generated revenue of $7.1 million during the year. The Company's strong start to this year demonstrates it has successfully navigated the downturn by focusing on supporting customers, advancing product development initiatives and implementing cost controls. The Company notes the recent increase in activity in core markets, and is well positioned to progress new contracts as the global economy begins to recover.

 

MYCELX also recently announced the sale of its building in Duluth, Georgia, USA, to right-size its office space needs across its main operating locations, as part of the cost reduction program. The sale enables MYCELX to achieve a financial gain of approximately $2.5 million. After the sale closes, the Company will have circa $6 million of cash and cash equivalents on the balance sheet.

 

Commenting on the market update, Connie Mixon, CEO, said:

 

"Following a challenging year, I am pleased to report that we are seeing an increase in activity in the markets in which we operate. This can be seen with the two contract extensions we have signed in Q1 2021, alongside the exciting opportunities arising from the paid trial for REGEN and our development of novel product applications. While we expect it to take time for the wider energy and industrial markets to normalize, we anticipate bidding activity by customers to increase, bolstered by the global economic recovery.

 

The Company continues to benefit from being in a financially robust position, following the cost reduction measures implemented in 2020 and the sale of the building in Duluth, and we look forward to keeping our stakeholders updated on our business progress over the coming months."

 

 

For further information please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Georgina McCooke

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

Notes to Editors

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the Oil and Gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.

www.mycelx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSUEFFEFSEED
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.